Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | F9 | P00740 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 10/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21944590 | 0.81 | KDM4A (0.45) | KDM5AMAOBMRGPRX4 | |
| SCHEMBL21944603 | 0.80 | MAOB (0.53) | MAOBMAOA | |
| SCHEMBL18002543 | 0.80 | MAOA (0.50) | HRH3KDM5AKDM5BF9F10 | |
| SCHEMBL21944596 | 0.78 | MRGPRX4 (0.48) | MAOBS1PR1MRGPRX4 | |
| SCHEMBL21944906 | 0.76 | MAOB (0.59) | MAOBMAOAMRGPRX4 | |
| SCHEMBL21945065 | 0.76 | CYP4F2 (0.41) | MAOBMRGPRX4 | |
| SCHEMBL16886123 | 0.76 | CYP1A2 (0.58) | MAOBFFAR1 | |
| SCHEMBL31183087 | 0.76 | CYP1A2 (0.58) | MAOBFFAR1 | |
| SCHEMBL26128487 | 0.75 | MAOB (0.60) | MAOBMAOA | |
| SCHEMBL17514959 | 0.75 | HRH3 (0.42) | HRH3KDM5AKDM5BF9F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | HRH3 4374/4885KDM5A 2810/4885KDM5B 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.